Close Menu

NanoString

NEW YORK (GenomeWeb) – NanoString Technologies announced after the close of the market on Monday a collaboration with Brigham and Women's Hospital aimed at accelerating genomic biomarker discoveries into clinical cancer diagnostics.

NEW YORK (GenomeWeb) – Through a gene expression-based analysis, a Broad Institute-led research team uncovered patterns of variability in T lymphocyte activation and immune response.

NEW YORK (GenomeWeb) – NanoString Technologies today filed a $100 million shelf registration with the US Securities and Exchange Commission.

NanoString Technologies announced the passing of J. Wayne Cowens, who had served as the firm's chief medical officer since 2011. He was 67 years old.

NEW YORK (GenomeWeb) – While most investors' eyes are on the adoption of NanoString Technologies' ProSigna Breast Cancer Gene Signature Assay, the firm's business with researchers continues to thrive.

NEW YORK (GenomeWeb) – NanoString Technologies said today that it has been told by Laboratory Corporation of America that UnitedHealthcare will reimburse for testing services from LabCorp based on NanoString's Prosigna Breast Cancer Gene Signature Assay.

NEW YORK (GenomeWeb) – NanoString Technologies reported after the close of the market Tuesday that its second quarter revenues increased 51 percent year over year.
Shares in NanoString fell in Wednesday morning trade, however, on concerns about reimbursement for its Prosigna test.

NEW YORK (GenomeWeb) – An international team of academic and industry researchers this week published the results of a comparison of commercially available platforms for microRNA expression analysis, finding that each has its own strengths and shortcomings that should be considered before selecti

NEW YORK (GenomeWeb News) – Researchers at the University of California, Berkeley have developed a method for performing single-cell western blotting.

NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market Tuesday that it will develop a companion diagnostic test for Celgene's Revlimid (lenalidomide), which the firm is developing for diffuse large B-cell lymphoma.

Pages

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.